Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{156537,
        author = {A Pandey and Shalu},
        title = {Immunomodulators; used in the treatment of covid-19},
        journal = {International Journal of Innovative Research in Technology},
        year = {},
        volume = {9},
        number = {4},
        pages = {123-133},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=156537},
        abstract = {The novel coronavirus pandemic has emerged as one of the significant medical-health challenges of the current century. The World Health Organization has named this new virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Immumomodulators may effectively treat patients and reduce mortality rates. Various therapeutic compounds have been investigated and applied to mitigate the symptoms in COVID-19 patients and cure the disease. These drugs consist of IL-1, IL-6, and immunosuppressive. There is emerging data that immunomodulatory drugs could be protective at reducing certain features of SARS-CoV-2 and improving recovery. In this article we will discuss potential treatment options for SARS-CoV-2 using immunomodulatory drugs and at what stage of the condition they may be beneficial.},
        keywords = {SARS-CoV-2, ILS, CRS, TNF},
        month = {},
        }